FDA Determines Regulatory Review Period for VARUBI Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for VARUBI, a human drug product, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).